Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Kunpeng Wu; Kunpeng Wu; Kunpeng Wu; Yahua Li; Yahua Li; Yahua Li; Zongming Li; Zongming Li; Zongming Li; Zihe Zhou; Zihe Zhou; Zihe Zhou; Xiaoyong Ge; Xiaoyong Ge; Xiaoyong Ge; Yifan Li; Yifan Li; Yifan Li; Xinwei Han; Xinwei Han; Xinwei Han; Peng Chen; Kewei Ren; Kewei Ren; Kewei Ren

doi:10.3389/fonc.2023.1143578

Frontiers in Oncology (Sep 2023)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Kunpeng Wu,
Kunpeng Wu,
Kunpeng Wu,
Yahua Li,
Yahua Li,
Yahua Li,
Zongming Li,
Zongming Li,
Zongming Li,
Zihe Zhou,
Zihe Zhou,
Zihe Zhou,
Xiaoyong Ge,
Xiaoyong Ge,
Xiaoyong Ge,
Yifan Li,
Yifan Li,
Yifan Li,
Xinwei Han,
Xinwei Han,
Xinwei Han,
Peng Chen,
Kewei Ren,
Kewei Ren,
Kewei Ren

Affiliations

Kunpeng Wu: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Kunpeng Wu: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Kunpeng Wu: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Yahua Li: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Yahua Li: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Yahua Li: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Zongming Li: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Zongming Li: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Zongming Li: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Zihe Zhou: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Zihe Zhou: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Zihe Zhou: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Xiaoyong Ge: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Xiaoyong Ge: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Xiaoyong Ge: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Yifan Li: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Yifan Li: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Yifan Li: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Xinwei Han: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Xinwei Han: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Xinwei Han: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China
Peng Chen: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Kewei Ren: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Kewei Ren: Interventional Institute of Zhengzhou University, Zhengzhou, Henan, China
Kewei Ren: Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, China

DOI: https://doi.org/10.3389/fonc.2023.1143578
Journal volume & issue: Vol. 13

Abstract

Read online

PurposeThis study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.Material and methodsIn this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).ResultsA total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment.ConclusionTACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords